Omeros reports $11.1 million in Q1 YARTEMLEA gross revenues, projecting company-wide positive cash flow within 18 months.
Omeros posted $11.1 million in gross revenues for YARTEMLEA in Q1 2026, with net revenues of $9.9 million after 11% gross-to-net adjustments. The company attributed the performance to strong early demand and uptake for the therapy targeting TA-TMA.
Management expects YARTEMLEA’s momentum to drive company-wide positive cash flow within the next 18 months. The Q1 figures mark an early milestone for the product’s commercial launch, though prior quarterly benchmarks were not disclosed.
No immediate market reaction was detailed in the earnings call insights.